Structure Therapeutics Obesity Candidate Is 'Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Portfolio Pulse from Vandana Singh
Structure Therapeutics Inc. (NASDAQ: GPCR) revealed positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, showing a significant weight decrease. Cantor Fitzgerald maintains an Overweight rating with a $65 price target, noting GSBR-1290's competitiveness with Eli Lilly's (NYSE: LLY) orforglipron. The study's rapid titration schedule led to high GI events, but these are expected to reduce with a slower schedule without affecting efficacy.
June 03, 2024 | 7:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Structure Therapeutics' GSBR-1290 showed significant weight loss in Phase 2a study. Cantor Fitzgerald maintains Overweight rating with a $65 price target, noting its competitiveness with Eli Lilly's orforglipron. GI events expected to reduce with slower titration.
The positive Phase 2a results and the maintained Overweight rating with a high price target from Cantor Fitzgerald are likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Eli Lilly's orforglipron is noted as a competitive benchmark for Structure Therapeutics' GSBR-1290. Despite high GI events in early trials, improvements are expected in later phases.
While Structure Therapeutics' GSBR-1290 shows promise, Eli Lilly's orforglipron remains a strong competitor. The news may not significantly impact LLY's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50